SciELO - Scientific Electronic Library Online

 
vol.135 número6Índice de medicina preventiva: Una medida integradora de la cobertura de los programas preventivosInteracción entre genotipo y nutrición: interpretación de estudios epidemiológicos índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

GARCIA B, Leonel; GALVEZ G, Javier  y  ARMENDARIZ B, Juan. Therapeutical targets for revert liver fibrosis. Rev. méd. Chile [online]. 2007, vol.135, n.6, pp.783-791. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872007000600015.

Liver fibrosis is the common response to chronic liver injury, ultimately leading to cirrhosis and its complications: portal hypertension, liver failure, hepatic encephalopathy, and hepatocellular carcinoma and others. Efficient and well-tolerated antifibrotic drugs are still lacking, and current treatment of hepatic fibrosis is limited to withdrawal of the noxious agent. Efforts over the past decade have mainly focused on fibrogenic cells generating the scarring response, although promising data on inhibition of parenchymal injury or reduction of liver inflammation have also been obtained. A large number of approaches have been validated in culture studies and in animal models, and several clinical trials are underway or anticipated for a growing number of molecules. This review highlight recent advances in the molecular mechanisms of liver fibrosis and discusses mechanistically based strategies that have recently emerged

Palabras clave : Fatty liver; Fibrosis; Liver cirrhosis.

        · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons